VFA
UTHR icon

Voya Financial Advisors’s United Therapeutics UTHR Stock Holding History

Voya Financial Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,602
Closed -$239K – 567
2017
Q4 		$239K Buy
+1,602
New +$204K 0.02% 479
2017
Q3 		– Sell
-1,770
Closed -$232K – 554
2017
Q2 		$232K Buy
+1,770
New +$221K 0.02% 443

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Voya Financial Advisors's UTHR Position: Q1 2018 in Review

Voya Financial Advisors sold out of United Therapeutics (UTHR) in Q1 2018, closing a stake of 1,602 shares — an estimated $239K sold.

Voya Financial Advisors first reported a position in UTHR in Q2 2017 and held it in 2 quarters. The position peaked at $239K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q1 2018.

  • Voya Financial Advisors reported no remaining United Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Voya Financial Advisors sold 1,602 United Therapeutics shares in Q1 2018, an estimated $239K.
  • Voya Financial Advisors first reported a position in United Therapeutics in Q2 2017 and held it in 2 quarters.
  • Voya Financial Advisors's United Therapeutics position peaked at $239K in Q4 2017.
  • 374 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2018.

Based on Voya Financial Advisors's 13F filing for Q1 2018, filed 15 May 2018.